ICLR Stock Overview
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ICLR from our risk checks.
ICON Public Limited Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$297.93 |
| 52 Week High | US$344.77 |
| 52 Week Low | US$181.92 |
| Beta | 1.16 |
| 1 Month Change | -10.26% |
| 3 Month Change | 12.97% |
| 1 Year Change | 46.60% |
| 3 Year Change | 38.53% |
| 5 Year Change | 118.14% |
| Change since IPO | 4,584.80% |
Recent News & Updates
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21
ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05Recent updates
What Does ICON Public Limited Company's (NASDAQ:ICLR) Share Price Indicate?
Apr 21ICON Public Limited Company's (NASDAQ:ICLR) Intrinsic Value Is Potentially 33% Above Its Share Price
Apr 05ICON Public Limited Company (NASDAQ:ICLR) Looks Just Right With A 27% Price Jump
Mar 05With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Feb 07ICON: Will The Huge Acquisition Of PRA Continue To Create Synergies?
Feb 01These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Jan 23Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jan 08What You Can Learn From ICON Public Limited Company's (NASDAQ:ICLR) P/E
Dec 24A Look At The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Dec 09With EPS Growth And More, ICON (NASDAQ:ICLR) Makes An Interesting Case
Nov 08Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Oct 09Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Sep 23Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Sep 05Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 03Is It Too Late To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)?
Jun 30Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Jun 12Calculating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
May 23Should You Think About Buying ICON Public Limited Company (NASDAQ:ICLR) Now?
Mar 29Is ICON (NASDAQ:ICLR) Using Too Much Debt?
Mar 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 28%?
Feb 21Why ICON Public Limited Company (NASDAQ:ICLR) Could Be Worth Watching
Dec 28These 4 Measures Indicate That ICON (NASDAQ:ICLR) Is Using Debt Reasonably Well
Dec 10Is ICON Public Limited Company (NASDAQ:ICLR) Trading At A 26% Discount?
Nov 22Icon selected by BARDA to conduct anthrax vaccine clinical trial
Oct 06Is ICON Public Limited Company (NASDAQ:ICLR) Potentially Undervalued?
Sep 15ICON (NASDAQ:ICLR) Seems To Use Debt Quite Sensibly
Aug 26Baron Funds - ICON Plc: Positioned For An Extended Period Of Revenue And Earnings Growth
Aug 11Are Investors Undervaluing ICON Public Limited Company (NASDAQ:ICLR) By 41%?
Aug 01Icon Q2 2022 Earnings Preview
Jul 26ICON (NASDAQ:ICLR) Has A Pretty Healthy Balance Sheet
May 11ICON Public Limited Company (NASDAQ:ICLR) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 20Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Feb 16We Think ICON (NASDAQ:ICLR) Can Stay On Top Of Its Debt
Jan 26Estimating The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)
Jan 05Is There Now An Opportunity In ICON Public Limited Company (NASDAQ:ICLR)?
Oct 31ICON (NASDAQ:ICLR) Has A Rock Solid Balance Sheet
Oct 16Estimating The Fair Value Of ICON Public Limited Company (NASDAQ:ICLR)
Oct 01ICON PLC: An Easy Stock To Choose For Diversified Exposure To Healthcare And Clinical Research
Aug 26Does ICON (NASDAQ:ICLR) Deserve A Spot On Your Watchlist?
Aug 07Shareholder Returns
| ICLR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.3% | -4.1% | -3.2% |
| 1Y | 46.6% | -6.7% | 19.3% |
Return vs Industry: ICLR exceeded the US Life Sciences industry which returned -6.7% over the past year.
Return vs Market: ICLR exceeded the US Market which returned 19.3% over the past year.
Price Volatility
| ICLR volatility | |
|---|---|
| ICLR Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ICLR has not had significant price volatility in the past 3 months.
Volatility Over Time: ICLR's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 41,100 | Steve Cutler | www.iconplc.com |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
ICON Public Limited Company Fundamentals Summary
| ICLR fundamental statistics | |
|---|---|
| Market cap | US$24.58b |
| Earnings (TTM) | US$612.34m |
| Revenue (TTM) | US$8.12b |
40.1x
P/E Ratio3.0x
P/S RatioIs ICLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICLR income statement (TTM) | |
|---|---|
| Revenue | US$8.12b |
| Cost of Revenue | US$5.71b |
| Gross Profit | US$2.41b |
| Other Expenses | US$1.80b |
| Earnings | US$612.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 24, 2024
| Earnings per share (EPS) | 7.42 |
| Gross Margin | 29.65% |
| Net Profit Margin | 7.54% |
| Debt/Equity Ratio | 40.9% |
How did ICLR perform over the long term?
See historical performance and comparison